Sanjay J. Mathew, MD

Baylor College of Medicine, Houston, Texas

  • 10Articles
  • 70.3KReads
  • 2006–2025Active
  • 52Collaborators
  • 374Citations

About

Sanjay J. Mathew, MD is affiliated with Baylor College of Medicine, Houston, Texas. Sanjay J. Mathew has authored or co-authored 10 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2006 and 2025. Their work focuses on Depression (MDD), Anxiety, and Electroconvulsive Therapy.

Publications

JCP
Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
Original Research

Comparing the Cognitive Effects of Repeated IV Ketamine and ECT in Patients with Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial

September 3, 2025

Patients treated with ketamine demonstrated superior cognitive functioning compared with those treated with ECT following a 3-week treatment course. No differences between treatments were observed among responders in at...
, , , et al
JCP
Difficult to Treat Depression: Focus on Approach, Algorithms, and Access
Academic Highlights

Difficult to Treat Depression: Focus on Approach, Algorithms, and Access

November 25, 2024

The Southwest Forum on Difficult to Treat Depression brought together 11 experts to discuss aspects of managing difficult-to-treat depression. This article presents highlights from the forum, covering such topics...
, , , et al
JCP
Rapidity of Improvement With Intranasal Esketamine for MDD
Meta-Analysis

Rapidity of Improvement With Intranasal Esketamine for MDD

December 12, 2022

This meta-analysis found that augmenting antidepressants with intranasal esketamine vs placebo was more effective in reducing depression severity at 24 hours and study endpoint.
, , , et al
JCP
Effect of Benzodiazepines on Antidepressant Effects of Ketamine
Original Research

Effect of Benzodiazepines on Antidepressant Effects of Ketamine

November 14, 2022

Findings of studies examining the impact of benzodiazepines on antidepressant effects of ketamine are contradictory. This study assessed whether concomitant oral benzodiazepines differentially affected treatment response to ketamine versus...
, , , et al
JCP
Meta-Analysis

Vortioxetine for Major Depressive Disorder

June 15, 2021

Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in...
, , , et al
JCP
Meta-Analysis

Esketamine Augmentation in Major Depressive Disorder

May 26, 2020

The FDA has now approved intranasal esketamine as augmention in treatment-resistant depression, and recent studies of its efficacy have been encouraging. This meta-analysis synthesizes the evidence to provide an...
, , , et al
JCP
Original Research

Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression

September 2, 2014

, , , et al
JCP
Letter to the Editor

A Case of Sustained Remission Following an Acute Course of Ketamine in Treatment-Resistant Depression

March 15, 2011

, , , et al
JCP
Article

Etiology and Neurobiology of Social Anxiety Disorder

November 15, 2006

,
JCP
Academic Highlights

Managing Patients With Vascular Disease and Depression.

October 16, 2006

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe